Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

Sponsor: Richmond Research Institute

NCT ID: NCT06809686

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 24 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
45 Years to 80 Years
Who
All
Number of participants
1,000
Started
2025-02-05
Last checked
2026-05

Plain English Summary

What is this study?

  • • Testing a new treatment for heart failure
  • • Clinical study - 1,000 participants
  • • The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease

Who can take part?

  • • Ages 45 Years to 80 Years
  • • Diagnosed with heart failure

Where?

  • • London - Richmond Pharmacology
  • • London - Richmond Pharmacology

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.

More detail

Patients with heart failure with mildly reduced or preserved ejection fraction will be invited to participate in this patient observational study. After providing informed consent, participants will then undergo a series of clinical assessments, and the participants' ECGs will be used to contribute to establishing an ECG library for future heart disease research. Additionally, patients' perspectives on the current standard of care clinical procedures will be gathered. Patient preferences will be gathered in relation to factors around routine clinical investigations for heart failure to better design a disease monitoring tool to include clinical and patient preferences. Also, the patients may be updated on the latest therapy options. Additionally, participants may be invited to review and provide feedback on the study design of heart failure trials under development, helping to ensure alignment with patient needs. Their input can identify potential procedure challenges and enhance the clarity of study materials, improving overall patient engagement. A follow-up call with a research physician will provide the opportunity to discuss any issues identified in the clinical baseline assessment and allow the participant to ask any additional questions.

Heart Failure

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 45 Years - 80 Years
  • Who can join: All genders

Biomarkers mentioned

results positive

What the study is looking for

  • ✓Male or female participants aged 45 to 80 years (inclusive) at the date of signing the agreement to take part.
  • ✓Diagnosed with heart failure.
  • ✓Able and willing to provide agreement to take part to participate.

Who cannot take part

  • ✗Diagnostic test results positive for:
  • ✗HIV-1 or HIV-2 infection
  • ✗Hepatitis B or Hepatitis C infection
  • ✗Any condition judged by the Investigator to pose an undue risk while participating in the trial
  • ✗Diagnostic results which are inconsistent with heart failure with mildly reduced or preserved ejection fraction as...
See the full criteria
Inclusion Criteria: 1. Male or female participants aged 45 to 80 years (inclusive) at the date of signing the informed consent. 2. Diagnosed with heart failure. 3. Able and willing to provide informed consent to participate. Exclusion Criteria: 1. Diagnostic test results positive for: 1. HIV-1 or HIV-2 infection 2. Hepatitis B or Hepatitis C infection 2. Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator. 3. Any condition judged by the Investigator to pose an undue risk while participating in the trial 4. Diagnostic results which are inconsistent with heart failure with mildly reduced or preserved ejection fraction as judged by the Investigator.

Where Is This Study? (2 UK sites)

Richmond Pharmacology

London SE1 1YR, United Kingdom

Recruiting
Site contact (verified)

Richmond Pharmacology

London SE1 1YR, United Kingdom

Recruiting

How to Get in Touch

Volunteer Recruitment Team

Sponsor contact

CONTACT

+44 (0) 207 042 5800 volunteer@richmondpharmacology.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-05